Should I Buy ABVX? ABVX 2026 Analysis

Should You Buy Abivax SA (ABVX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

114.170

1 Day change

0.17%

52 Week Range

148.830

Analysis Updated At

2026/01/28

Buy now for a long-term position. The near-term chart is soft (bearish MACD, price below pivot), but the longer-term setup is driven by strong Phase 3 ulcerative colitis data and multiple 2026 catalysts, with Wall Street staying uniformly bullish and price targets well above the current ~$118.9 level.

Technical Analysis

Pre-market price is ~118.88, still below the pivot (121.274), implying the stock is currently trading under a key decision level. Momentum is weak-to-bearish: MACD histogram is negative (-0.511) and expanding lower, suggesting downside pressure persists. RSI(6) at ~42.6 is neutral but leaning weak (not oversold). Moving averages are converging, which often precedes a larger move; given the negative MACD, the immediate bias is slightly down. Key levels: Support S1 ~114.883 (then S2 ~110.935); Resistance R1 ~127.665 (then R2 ~131.613). Pattern-based odds provided also point to potential softness over the next week (-4%), with modest recovery over the next month (+1.61%). Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning leans bullish: both open interest put/call (0.53) and volume put/call (0.34) indicate more call interest than puts. Activity is elevated (today’s volume ~205.77% of 30-day average), signaling heightened attention. Implied volatility is very high (30D IV ~93.33; IV percentile ~95.35), which typically reflects the market pricing in meaningful upcoming moves/catalysts and strong speculative interest. Net: sentiment is risk-on/bullish, with the market willing to pay up for upside exposure.

Technical Summary

Sell

Buy

Positive Catalysts

1) Strong clinical narrative around obefazimod: analysts cite encouraging magnitude of effect and tolerability profile in Phase 3 induction for ulcerative colitis (UC). 2) Clear, dated upcoming milestones: Phase 3 maintenance readout expected in 2Q26; Phase 2b Crohn’s disease data expected in 2H26—both are major event-driven catalysts for a biotech name. 3) Street support is broad and strengthening (multiple price target raises in recent weeks), which often supports follow-on institutional demand.
Influential / political flows: No recent congress trading data available; hedge funds and insiders are reported neutral with no significant recent trend.

Neutral/Negative Catalysts

1) Near-term technicals are not supportive: negative/weak momentum (bearish MACD), price below pivot, and pattern stats imply potential near-term drawdown risk. 2) Options are pricing big moves (very high IV), which can coincide with sharp swings around clinical updates. 3) No fresh news this week to act as an immediate upside trigger; the next major catalysts are mostly in 2026.

Financial Performance

Financial snapshot was not available from the provided data (error returned), so the latest quarter/season and growth trends cannot be assessed here. Based on the dataset, the current investment case is primarily catalyst/clinical-progress driven rather than near-term revenue/earnings driven.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend is strongly positive, with repeated price target increases and consistent Buy/Overweight/Outperform ratings. Notable raises include Morgan Stanley to $145 (from $101) and BTIG to $150 (from $120), alongside prior bullish targets up to $175–$176 (Guggenheim/Wolfe). Wall Street pros: compelling clinical profile for obefazimod in UC, multiple 2026 catalysts (UC maintenance + Crohn’s), and growing conviction in market opportunity. Wall Street cons: the story is largely catalyst-dependent and timing-driven, meaning sentiment can shift quickly if timelines/data disappoint.

9 Analyst Rating

Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 153.88 USD with a low forecast of 131 USD and a high forecast of 176 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 113.980

Low

131

Averages

153.88

High

176

Current: 113.980

Low

131

Averages

153.88

High

176

Morgan Stanley

Overweight

maintain

$101 -> $145

AI Analysis

2026-01-09

Reason

Morgan Stanley

Price Target

$101 -> $145

AI Analysis

2026-01-09

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Abivax to $145 from $101 and keeps an Overweight rating on the shares after the company provided its 2026 corporate outlook highlighting new market research and clinical progress ahead of next week's investment conference in San Francisco. As the firm has continued to interrogate the market opportunity for obefazimod in UC, it has found that experts are increasingly encouraged by both the magnitude of effect and tolerability profile demonstrated in the induction portion of the Phase 3 program, the analyst added.

BTIG

Julian Harrison

Buy

maintain

$120 -> $150

2026-01-08

Reason

BTIG

Julian Harrison

Price Target

$120 -> $150

2026-01-08

maintain

Buy

Reason

BTIG analyst Julian Harrison raised the firm's price target on Abivax to $150 from $120 and keeps a Buy rating on the shares. Abivax provided an updated 2026 pipeline outlook highlighting strong Phase 3 ABTECT induction data for obefazimod, positioning it as a preferred, flexible oral option across the moderate-to-severe treatment paradigm, with no new safety signals reported to date, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABVX

Unlock Now

ABVX Should I Buy

ABVX Should I Buy

Should You Buy Abivax SA (ABVX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch